Zohar Tadmor-Eilat - 18 Mar 2026 Form 3 Insider Report for Cellebrite DI Ltd. (CLBT)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 08:28:11 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Zohar Tadmor-Eilat

Key filing fact

Zohar Tadmor-Eilat filed Form 3 for Cellebrite DI Ltd. (CLBT) on 18 Mar 2026.

Key facts

  • This page summarizes Zohar Tadmor-Eilat's Form 3 filing for Cellebrite DI Ltd. (CLBT).
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 08:28.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001970909 Primary reporting owner

Tadmor-Eilat Zohar

Relationship
Chief People Officer
Address
94 SHLOMO SHMELZER ROAD, PETAH TIKVA, ISRAEL
Signature
/s/ Zohar Tadmor-Eilat
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLBT holding

Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
129,814
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1, F2, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLBT holding Derivative

Stock options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
22,722
Exercise price
$4.95
Footnotes
F6
CLBT holding Derivative

Stock options

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
28,236
Exercise price
$11.51
Footnotes
F7
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Includes 21,988 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on February 14, 2023, of which 5,497 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

Footnote F2

Includes 15,615 Ordinary Shares that are represented by RSUs that were granted on March 20, 2024, of which 1,735 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.

Footnote F3

Includes 11,760 Ordinary Shares that are represented by RSUs that were granted on February 11, 2025, of which 980 vest on each of May 11, 2026 and every three months thereafter through February 11, 2029.

Footnote F4

Includes 3,471 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on March 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through March 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement.

Footnote F5

Includes 39,491 Ordinary Shares that are represented by RSUs that were granted on February 10, 2026 and vest as follows: 9,875 vest on the first anniversary of the grant date and 2,468 vest every three months thereafter through February 10, 2030.

Footnote F6

Of these stock options, 7,574 are fully vested and exercisable and 3,787 vest on each of May 14, 2026 and every three months thereafter through February 14, 2027.

Footnote F7

Of these stock options, 12,360 are fully vested and exercisable and 1,764 vest on each of March 20, 2026 and every three months thereafter through March 20, 2028.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .